Condition: Renal Cancer · Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna
To evaluate the utility of dual-energy spectral computed tomography (CT) scan in monitoring treatment in patients with metastatic clear cell carcinoma of the kidney. In particular, to analyze the use of spectral CT in patients who are candidates to receive first-line treatment based on combinations of immunotherapy and molecularly targeted drugs. In particular, the parameters derived from the use of this technology and their variation during therapy will be analyzed together with some possible molecular alterations highlighted by the analysis of the tumor tissue previously taken from the patient, relating them to the response to first-line therapy with immuno-combinations.
This description comes directly from the study's public registry record.
Francesco FM Massari, MD · 0511242204 · francesco.massari@aosp.bo.it
Always discuss trial participation with your own doctor first.
| Irccs Azienda Ospedaliero Universitario Di Bologna | Bologna, BO, Italy | Recruiting |
| Oncology Unit, IRCCS Azienda Ospedaliero Universitaria Bologna | Bologna, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06863857